Abstract:Peptides, defined as polymers of less than 50 amino acids with a molecular weight of less than 10 kDa, represent a fast-growing class of new therapeutics which has unique pharmacokinetic characteristics compared to large proteins or small molecule drugs. Unmodified peptides usually undergo extensive proteolytic cleavage, resulting in short plasma half-lives. As a result of their low permeability and susceptibility to catabolic degradation, therapeutic peptides usually have very limited oral bioavailability and are administered either by the intravenous, subcutaneous, or intramuscular route, although other routes such as nasal delivery are utilized as well. Distribution processes are mainly driven by a combination of diffusion and to a lesser degree convective extravasation dependent on the size of the peptide, with volumes of distribution frequently not larger than the volume of the extracellular body fluid. Owing to the ubiquitous availability of proteases and peptidases throughout the body, proteolytic degradation is not limited to classic elimination organs. Since peptides are generally freely filtered by the kidneys, glomerular filtration and subsequent renal metabolism by proteolysis contribute to the elimination of many therapeutic peptides. Although small peptides have usually limited immunogenicity, formation of anti-drug antibodies with subsequent hypersensitivity reactions has been described for some peptide therapeutics. Numerous strategies have been applied to improve the pharmacokinetic properties of therapeutic peptides, especially to overcome their metabolic instability, low permeability, and limited tissue residence time. Applied techniques include amino acid substitutions, modification of the peptide terminus, inclusion of disulfide bonds, and conjugation with polymers or macromolecules such as antibody fragments or albumin. Application of model-based pharmacokinetic–pharmacodynamic correlations has been widely used for therapeutic peptides in support of drug development and dosage regimen design, especially because their targets are often well-described endogenous regulatory pathways and processes.

D-Peptides As Recognition Molecules and Therapeutic Agents

Bioactive Peptides of Plant Origin: Distribution, Functionality, and Evidence of Benefits in Food and Health

Molecular Mechanistic Insights into Dipeptidyl Peptidase-IV Inhibitory Peptides to Decipher the Structural Basis of Activity

A Comprehensive Review on Current Advances in Peptide Drug Development and Design

Peptides as Targeting Agents and Therapeutics: A Brief Overview

Research Progress on Dipeptidyl Peptidase Family: Structure, Function and Xenobiotic Metabolism

Peptides for therapeutic applications – challenges and chances

Therapeutic peptides: current applications and future directions

Peptide Aptamers with Biological and Therapeutic Applications

Recent Developments in Therapeutic Peptides for the Glucagon-like Peptide 1 and 2 Receptors

Therapeutic Peptides Targeting PPI in Clinical Development: Overview, Mechanism of Action and Perspectives

Design and Synthetic Strategies for Helical Peptides.

Pharmacokinetics and Pharmacokinetic–Pharmacodynamic Correlations of Therapeutic Peptides

A Further Realization on the Recognition of Proteins.

Disulfide-constrained peptide scaffolds enable a robust peptide-therapeutic discovery platform

Novel Strategy Utilizing Extracellular Cysteine-Rich Domain of Membrane Receptor for Constructing D-Peptide Mediated Targeted Drug Delivery Systems: A Case Study on Fn14

D-Amino Acids and D-Amino Acid-Containing Peptides: Potential Disease Biomarkers and Therapeutic Targets?

Dephosphorylation of D-peptide Derivatives to Form Biofunctional, Supramolecular Nanofibers/hydrogels and Their Potential Applications for Intracellular Imaging and Intratumoral Chemotherapy.

Synthesis And Applications Of Peptide Dendrimer

A Diaminodiacid (DADA) Strategy for the Development of Disulfide Surrogate Peptides

Preparation, structural properties, and in vitro and in vivo activities of peptides against dipeptidyl peptidase IV (DPP-IV) and α-glucosidase: a general review